NCT06611579NARecruiting
Clinical Study of the inQB8 TTVR System (The MonarQ Study)
inQB8 Medical Technologies, LLC
Start Date
6/1/2025
Completion Date
10/31/2030
Summary
Prospective, multi-center study to assess safety and performance of the inQB8 MonarQ Tricuspid Valve Replacement System.
Detailed Description
The study is a multi-center, prospective, single-arm study to assess safety and performance of the inQB8 Medical Technologies MonarQ Tricuspid Valve Replacement System.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* Anatomically suitable for the MonarQ TTVR System
* Symptomatic, tricuspid regurgitation (TR) that is severe or greater
* Adequately treated for heart failure based upon medical standards
* Hemodynamically stable
Exclusion Criteria:
* Need for emergent or urgent surgery for any reason, any planned cardiac surgery within the next 12 months (365 days), or any planned percutaneous cardiac procedure within the next 90 days
* Refractory Heart Failure (HF) that requires or required advanced intervention
* Any condition, in the opinion of the investigator, making it unlikely the patient will be able to complete all protocol procedures and follow-up.
* Currently participating in another investigational biologic, drug or device study
Interventions
DEVICE
Transcatheter Tricuspid Valve Replacement
Conditions
Tricuspid Valve Regurgitation
Locations
Cedars-Sinai Medical Center
Los Angeles, California 90048
United States
Los Robles Hosptial and Medical Center
Thousand Oaks, California 91360
United States
Piedmont Atlanta Hospital
Atlanta, Georgia 30309
United States
North Shore University Hospital
Manhasset, New York 11030
United States
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania 19104
United States
Baylor Heart Hospital
Plano, Texas 75093
United States
AZ Sint-Jan Brugge AV
Bruges, 8000
Belgium
St. Michael's Hospital
Toronto, Ontario M5B1W8
Canada